Furthermore, Allo significantly reduced inflammasome activation by downregulating the expression of Nlrc4 and Pycard. Additionally, Allo activated the TGFB1 signaling pathway, consistent with Allo’s effect on TGFB1 signaling in cancer cell models (69). Here, NLRC4 is linked to cancer.